Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Sandra Schläfke"'
Autor:
Markus Dold, Hans-Jürgen Möller, Hans-Peter Volz, Erich Seifritz, Sandra Schläfke, Lucie Bartova, Siegfried Kasper
Publikováno v:
European Psychiatry, Vol 67 (2024)
The influence of baseline severity on the efficacy of Silexan, a proprietary essential oil from Lavandula angustifolia, in anxiety disorders has not been investigated in a pooled dataset. We report on an individual patient data analysis of all five d
Externí odkaz:
https://doaj.org/article/59fec36673804aceac6eb4542d3e1459
Autor:
Markus Dold, Lucie Bartova, Hans-Peter Volz, Erich Seifritz, Hans-Jürgen Möller, Sandra Schläfke, Siegfried Kasper
Publikováno v:
European Archives of Psychiatry and Clinical Neuroscience.
Introduction We report on a meta-analysis of Silexan, a proprietary active substance produced from Lavandula angustifolia, in subthreshold anxiety, mixed anxiety and depressive disorder (MADD), and generalized anxiety disorder (GAD). Methods The pres
Autor:
Talar Hopyan, Anna Wacker, Sandra Schläfke, Walter E. Müller, Hans-Peter Volz, Hans-Jürgen Möller, Erich Seifritz, Siegfried Kasper
Publikováno v:
International Journal of Neuropsychopharmacology
Background Silexan is a lavender essential oil with established anxiolytic and calming efficacy. Here we asked whether there is a potential for abuse in human patients. Methods We carried out a phase I abuse liability single-center, double-blind, 5-w
Publikováno v:
Zeitschrift für Phytotherapie.
Autor:
Sandra Schläfke, Siegfried Kasper, Markus Gastpar, Walter E. Müller, Angelika Dienel, Hans-Peter Volz, H.-J. Möller
Publikováno v:
International Journal of Psychiatry in Clinical Practice. 21:177-180
Subsequent to a randomised, double-blind, double dummy clinical trial assessing the efficacy of silexan compared to placebo and paroxetine in patients suffering from generalised anxiety disorder (GAD), a 1week follow-up phase was added in order to as
Publikováno v:
European Neuropsychopharmacology. 26:331-340
Mixed anxiety and depressive disorder (MADD; ICD-10 F41.2) is a condition characterized by subsyndromal symptoms of anxiety and depression, neither of which are clearly predominant. Silexan has been demonstrated to be efficacious in subsyndromal and
Publikováno v:
Journal of psychiatric research. 115
Disturbed sleep is among the most prevalent hyperarousal symptoms in anxiety disorders. Most drugs recommended for anxiety and insomnia have a sedating effect which is related to their beneficial effect on disturbed sleep. Silexan is a proprietary es
Publikováno v:
International clinical psychopharmacology. 32(4)
Silexan, a special active substance produced from Lavandula angustifolia, is efficacious in subsyndromal anxiety at a dose of 80 mg/day, but its effective dosage in generalized anxiety disorder (GAD) has yet to be defined. In two double-blind, placeb
Publikováno v:
World Journal of Urology. 32:1149-1154
To determine the effects of the herbal fixed-dose combination PRO 160/120 (extracts from saw palmetto fruits and stinging nettle roots) on nocturnal voiding frequency, as measured by question 7 of the IPSS questionnaire, in patients with moderate-to-
Publikováno v:
GeroPsych. 27:75-80
Using data from two randomized, placebo-controlled trials involving 806 outpatients, we performed linear regression analyses to evaluate how cognitive abilities in patients with dementia assessed by the SKT (Syndrom-Kurztest – Short Cognitive Perfo